DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Rummel MJ, Niederle N, Maschmeyer G. et al.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet 2013;
381: 1203-1210
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.